TRAILR1/TNFRSF10A Antibody MAB347-100 from R&D Systems, a Bio-Techne Brand

Product Specs
ItemTRAILR1/TNFRSF10A Antibody
CompanyR&D Systems, a Bio-Techne Brand
Price Pricing Info Supplier Page View Company Product Page
Catalog NumberMAB347-100
Quantity100 ug (also 500 ug, 25 ug)
ApplicationsFlow Cytometry, Immunohistochemistry, CyTOF-ready
Conjugate/TagUnconjugated
FormatLyophilized from a 0.2 µm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS
ReactivityHuman
TargetTRAILR1/TNFRSF10A
IsotypeIgG1
Clone69036
HostMouse
ImmunogenS. frugiperda insect ovarian cell line Sf 21-derived recombinant human TRAIL R1/TNFRSF10A, Ala24-Asn239, Accession # AAC51226
NCBI Full Gene NameTNF receptor superfamily member 10a
NCBI Gene AliasesAPO2, CD261, DR4, TRAILR-1, TRAILR1
ClonalityMonoclonal
Brand/TrademarkR&D Systems, a Bio-Techne Brand
PurityProtein A or G purified from hybridoma culture supernatant
Antibody TypePrimary Antibodies
StorageUse a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70 °C as supplied. 1 month, 2 to 8 °C under sterile conditions after reconstitution. 6 months, -20 to -70 °C under sterile conditions after reconstitution

Specifications/Features

Available conjugates: Unconjugated

Specificity: Detects recombinant human TRAIL R1/TNFRSF10A in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human (rh) TRAIL R2, rhTRAIL R3, rhTRAIL R4, or rhDcR3 is observed

Add to Compare List

R&D Systems, a Bio-Techne Brand

614 McKinley Place N.E.

Minneapolis, Minnesota 55413

United States

Phone: 1 (800) 343-7475
1 (612) 379-2956

Fax: 1 (612) 656-4400

Company Profile

Website: http://www.rndsystems.com

(1) Marizomib sensitizes primary glioma cells to apoptosis induced by a latest-generation TRAIL receptor agonistCell death & diseaseJune 24, 2021Boccellato C, Kolbe E, Peters N, Juric V, Fullstone G, Verreault M, Idbaih A, Lamfers MLM, Murphy BM, Rehm M.

(2) Stress-induced TRAILR2 expression overcomes TRAIL resistance in cancer cell spheroidsCell death and differentiationNovember 1, 2020Stöhr D, Schmid JO, Beigl TB, Mack A, Maichl DS, Cao K, Budai B, Fullstone G, Kontermann RE, Mürdter TE, et al.

(3) CD154 inhibits death of T cells via a Cis interaction with the α5β1 integrinPloS oneJanuary 1, 2020Bachsais M, Salti S, Zaoui K, Hassan GS, Aoudjit F, Mourad W.

(4) Bcl-2-mediated control of TRAIL-induced apoptotic response in the non-small lung cancer cell line NCI-H460 is effective at late caspase processing stepsPloS oneJanuary 1, 2018Danish L, Imig D, Allgöwer F, Scheurich P, Pollak N.

(5) Targeting Apoptotic Activity Against Prostate Cancer Stem CellsInternational journal of molecular sciencesJuly 29, 2017Jaworska D, Szliszka E.

(6) Caspase-8 expression is predictive of tumour response to death receptor 5 agonist antibody in Ewing's sarcomaBritish journal of cancerSeptember 15, 2015Kang Z, Goldstein SD, Yu Y, Meltzer PS, Loeb DM, Cao L.

(7) Interferon-β inhibits glioma angiogenesis through downregulation of vascular endothelial growth factor and upregulation of interferon inducible protein 10International journal of oncologyNovember 1, 2014Takano S, Ishikawa E, Matsuda M, Yamamoto T, Matsumura A.

(8) Dominant negative effects of tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 4 on TRAIL receptor 1 signaling by formation of heteromeric complexesThe Journal of biological chemistryJune 6, 2014Neumann S, Hasenauer J, Pollak N, Scheurich P.

(9) TRAIL-engineered bone marrow-derived mesenchymal stem cells: TRAIL expression and cytotoxic effects on C6 glioma cellsAnticancer researchFebruary 1, 2014Tang XJ, Lu JT, Tu HJ, Huang KM, Fu R, Cao G, Huang M, Cheng LH, Dai LJ, Zhang L.

(10) Crosstalk between mitochondrial ROS and depolarization in the potentiation of TRAIL-induced apoptosis in human tumor cellsInternational journal of oncologyFebruary 1, 2014Suzuki-Karasaki M, Ochiai T, Suzuki-Karasaki Y.

(11) Exosomes secreted by human placenta carry functional Fas ligand and TRAIL molecules and convey apoptosis in activated immune cells, suggesting exosome-mediated immune privilege of the fetusJournal of immunology (Baltimore, Md. : 1950)December 1, 2013Stenqvist AC, Nagaeva O, Baranov V, Mincheva-Nilsson L.

(12) Casticin potentiates TRAIL-induced apoptosis of gastric cancer cells through endoplasmic reticulum stressPloS oneJanuary 1, 2013Zhou Y, Tian L, Long L, Quan M, Liu F, Cao J.

(13) TRAIL-engineered pancreas-derived mesenchymal stem cells: characterization and cytotoxic effects on pancreatic cancer cellsCancer gene therapySeptember 1, 2012Moniri MR, Sun XY, Rayat J, Dai D, Ao Z, He Z, Verchere CB, Dai LJ, Warnock GL.

(14) The transmembrane domains of TNF-related apoptosis-inducing ligand (TRAIL) receptors 1 and 2 co-regulate apoptotic signaling capacityPloS oneJanuary 1, 2012Neumann S, Bidon T, Branschädel M, Krippner-Heidenreich A, Scheurich P, Doszczak M.

(15) Drozitumab, a human antibody to death receptor 5, has potent antitumor activity against rhabdomyosarcoma with the expression of caspase-8 predictive of responseClinical cancer research : an official journal of the American Association for Cancer ResearchMay 15, 2011Kang Z, Chen JJ, Yu Y, Li B, Sun SY, Zhang B, Cao L.

(16) Dexamethasone counteracts the anti-osteoclastic, but not the anti-leukemic, activity of TNF-related apoptosis inducing ligand (TRAIL)Journal of cellular physiologyFebruary 1, 2010Zauli G, Rimondi E, Celeghini C, Milani D, Secchiero P.

(17) Plasmacytoid dendritic cells express TRAIL and induce CD4+ T-cell apoptosis in HIV-1 viremic patientsBloodOctober 29, 2009Stary G, Klein I, Kohlhofer S, Koszik F, Scherzer T, Müllauer L, Quendler H, Kohrgruber N, Stingl G.

(18) Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signalsExperimental hematologyDecember 1, 2008Seal S, Hockenbery DM, Spaulding EY, Kiem HP, Abbassi N, Deeg HJ.

(19) Diallyl trisulfide increases the effectiveness of TRAIL and inhibits prostate cancer growth in an orthotopic model: molecular mechanismsMolecular cancer therapeuticsAugust 1, 2008Shankar S, Chen Q, Ganapathy S, Singh KP, Srivastava RK.

(20) P53-mediated upregulation of DcR1 impairs oxaliplatin/TRAIL-induced synergistic anti-tumour potential in colon cancer cellsOncogeneJuly 10, 2008Toscano F, Fajoui ZE, Gay F, Lalaoui N, Parmentier B, Chayvialle JA, Scoazec JY, Micheau O, Abello J, Saurin JC.

Be the First to Write a Review!

TRAILR1/TNFRSF10A Antibody

TRAILR1/TNFRSF10A Antibody

TRAILR1/TNFRSF10A Antibody

TRAILR1/TNFRSF10A Antibody from R&D Systems, a Bio-Techne Brand

Specifications/Features

R&D Systems, a Bio-Techne Brand

Citations (24)

Reviews

TRAILR1/TNFRSF10A Antibody from R&D Systems, a Bio-Techne Brand

About Biocompare

Advertise with Us

Specialized Search Tools

Site Map